New renal drug development to face chronic renal disease

Bibliography

• WHO maps noncommunicable disease trends in all countries: country profiles on noncommunicable disease trends in 193 countries. Cent Eur J Public Health 2011;19(3):130, 138
   Google Scholar
• Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl 2005(98):S7-S10
   Google Scholar
• SYSTEM USRD. 2013 Annual Data Report. 2013
   Google Scholar
• Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med 2000;247(3):301-10
   PubMed Web of Science ®Google Scholar
• Prakash S, O’Hare AM. Interaction of aging and chronic kidney disease. Semin Nephrol 2009;29(5):497-503
   PubMed Web of Science ®Google Scholar
• Bureau UC. US Census Bureau projections. 2013
   Google Scholar
• Clase CM, Gao P, Tobe SW, et al. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med 2011;154(5):310-18
   PubMed Web of Science ®Google Scholar
• Miyata T, Kikuchi K, Kiyomoto H, et al. New era for drug discovery and development in renal disease. Nat Rev Nephrol 2011;7(8):469-77
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366(9502):2026-33
   PubMed Web of Science ®Google Scholar
• Opie LH, Kowolik H. The discovery of captopril: from large animals to small molecules. Cardiovasc Res 1995;30(1):18-25
   PubMed Web of Science ®Google Scholar
• Novak JE, Inrig JK, Patel UD, et al. Negative trials in nephrology: what can we learn? Kidney Int 2008;74(9):1121-7
   PubMed Web of Science ®Google Scholar
• Hinz B, Phan SH, Thannickal VJ, et al. The myofibroblast: one function, multiple origins. Am J Pathol 2007;170(6):1807-16
   PubMed Web of Science ®Google Scholar
• Hinz B. The myofibroblast: paradigm for a mechanically active cell. J Biomech 2010;43(1):146-55
   PubMed Web of Science ®Google Scholar
• Grgic I, Campanholle G, Bijol V, et al. Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int 2012;82(2):172-83
   PubMed Web of Science ®Google Scholar
• Farris AB, Adams CD, Brousaides N, et al. Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol 2011;22(1):176-86
   PubMed Web of Science ®Google Scholar
• Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia 1971;27(5):549-50
   PubMedGoogle Scholar
• Hinz B, Phan SH, Thannickal VJ, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol 2012;180(4):1340-55
   PubMed Web of Science ®Google Scholar
• Gross O, Girgert R, Beirowski B, et al. Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Matrix Biol 2010;29(5):346-56
   PubMed Web of Science ®Google Scholar
• Ronco P, Chatziantoniou C. Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. Kidney Int 2008;74(7):873-8
   PubMed Web of Science ®Google Scholar
• Rubel D, Kruegel J, Martin M, et al. Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice. Matrix Biol 2014;34:13-21
   PubMed Web of Science ®Google Scholar
• Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214(2):199-210
   PubMed Web of Science ®Google Scholar
• Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18(7):1028-40
   PubMed Web of Science ®Google Scholar
• Rosenbloom J, Mendoza FA, Jimenez SA. Strategies for anti-fibrotic therapies. Biochim Biophys Acta 2013;1832(7):1088-103
   PubMed Web of Science ®Google Scholar
• Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 2012;82(5):516-24
   PubMed Web of Science ®Google Scholar
• Gagliardini E, Benigni A. Therapeutic potential of TGF-beta inhibition in chronic renal failure. Expert Opin Biol Ther 2007;7(3):293-304
   PubMed Web of Science ®Google Scholar
• Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56(1):323-33
   PubMed Web of Science ®Google Scholar
• Ma LJ, Yang H, Gaspert A, et al. Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol 2003;163(4):1261-73
   PubMed Web of Science ®Google Scholar
• Hahm K, Lukashev ME, Luo Y, et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol 2007;170(1):110-25
   PubMed Web of Science ®Google Scholar
• Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005;128(3):742-55
   PubMed Web of Science ®Google Scholar
• Wasmuth HE, Trautwein C. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Hepatology 2007;45(2):543-4
   PubMedGoogle Scholar
• Mann J, Chu DC, Maxwell A, et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010;138(2):705-14; 714 e1-4
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Bhattacharyya S, Lakos G, et al. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004;50(4):1305-18
   PubMed Web of Science ®Google Scholar
• Kawai T, Masaki T, Doi S, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009;89(1):47-58
   PubMed Web of Science ®Google Scholar
• Iekushi K, Taniyama Y, Azuma J, et al. Hepatocyte growth factor attenuates renal fibrosis through TGF-beta1 suppression by apoptosis of myofibroblasts. J Hypertens 2010;28(12):2454-61
   PubMed Web of Science ®Google Scholar
• Dai C, Saleem MA, Holzman LB, et al. Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria. Kidney Int 2010;77(11):962-73
   PubMed Web of Science ®Google Scholar
• Mizuno S, Matsumoto K, Nakamura T. HGF as a renotrophic and anti-fibrotic regulator in chronic renal disease. Front Biosci 2008;13:7072-86
   PubMed Web of Science ®Google Scholar
• Igarashi A, Nashiro K, Kikuchi K, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1996;106(4):729-33
   PubMed Web of Science ®Google Scholar
• Okada H, Kikuta T, Kobayashi T, et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005;16(1):133-43
   PubMed Web of Science ®Google Scholar
• Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004;363(9402):62-4
   PubMed Web of Science ®Google Scholar
• Phanish MK, Winn SK, Dockrell ME. Connective tissue growth factor-(CTGF, CCN2) – a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp Nephrol 2010;114(3):e83-92
   PubMed Web of Science ®Google Scholar
• Leask A, Sa S, Holmes A, et al. The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol Pathol 2001;54(3):180-3
   PubMedGoogle Scholar
• Pannu J, Asano Y, Nakerakanti S, et al. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 2008;58(8):2528-37
   PubMed Web of Science ®Google Scholar
• Adler SG, Schwartz S, Williams ME, et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010;5(8):1420-8
   PubMed Web of Science ®Google Scholar
• Eitner F, Bucher E, van Roeyen C, et al. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 2008;19(2):281-9
   PubMed Web of Science ®Google Scholar
• Martin IV, Borkham-Kamphorst E, Zok S, et al. Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis. Am J Pathol 2013;182(1):107-17
   PubMed Web of Science ®Google Scholar
• Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014;349(2):209-20
   PubMed Web of Science ®Google Scholar
• Alvarez RH, Kantarjian HM, Cortes JE. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006;81(9):1241-57
   PubMed Web of Science ®Google Scholar
• Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004;15(4):255-73
   PubMed Web of Science ®Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79(4):1283-316
   PubMed Web of Science ®Google Scholar
• Ostendorf T, Eitner F, Floege J. The PDGF family in renal fibrosis. Pediatr Nephrol 2012;27(7):1041-50
   PubMed Web of Science ®Google Scholar
• Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008;19(1):12-23
   PubMed Web of Science ®Google Scholar
• Abrass CK, Hansen KM, Patton BL. Laminin alpha4-null mutant mice develop chronic kidney disease with persistent overexpression of platelet-derived growth factor. Am J Pathol 2010;176(2):839-49
   PubMed Web of Science ®Google Scholar
• Moolenaar WH, van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004;26(8):870-81
   PubMed Web of Science ®Google Scholar
• Okudaira S, Yukiura H, Aoki J. Biological roles of lysophosphatidic acid signaling through its production by autotaxin. Biochimie 2010;92(6):698-706
   PubMed Web of Science ®Google Scholar
• Georas SN, Berdyshev E, Hubbard W, et al. Lysophosphatidic acid is detectable in human bronchoalveolar lavage fluids at baseline and increased after segmental allergen challenge. Clin Exp Allergy 2007;37(3):311-22
   PubMed Web of Science ®Google Scholar
• Tager AM, LaCamera P, Shea BS, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008;14(1):45-54
   PubMed Web of Science ®Google Scholar
• Swaney JS, Chapman C, Correa LD, et al. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther 2011;336(3):693-700
   PubMed Web of Science ®Google Scholar
• Pradere JP, Klein J, Gres S, et al. LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 2007;18(12):3110-18
   PubMed Web of Science ®Google Scholar
• Pradere JP, Gonzalez J, Klein J, et al. Lysophosphatidic acid and renal fibrosis. Biochim Biophys Acta 2008;1781(9):582-7
   PubMed Web of Science ®Google Scholar
• Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int 2011;80(9):915-25
   PubMed Web of Science ®Google Scholar
• Turner JM, Bauer C, Abramowitz MK, et al. Treatment of chronic kidney disease. Kidney Int 2012;81(4):351-62
   PubMed Web of Science ®Google Scholar
• Furuichi K, Kaneko S, Wada T. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 2009;13(1):9-14
   PubMed Web of Science ®Google Scholar
• Mathew A, Cunard R, Sharma K. Antifibrotic treatment and other new strategies for improving renal outcomes. Contrib Nephrol 2011;170:217-27
   PubMed Web of Science ®Google Scholar
• Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208(5):961-72
   PubMed Web of Science ®Google Scholar
• Goetzl EJ, Lee H, Azuma T, et al. Gelsolin binding and cellular presentation of lysophosphatidic acid. J Biol Chem 2000;275(19):14573-8
   PubMed Web of Science ®Google Scholar
• Nurden AT, Nurden P, Sanchez M, et al. Platelets and wound healing. Front Biosci 2008;13:3532-48
   PubMed Web of Science ®Google Scholar
• Kapoor M, Liu S, Huh K, et al. Connective tissue growth factor promoter activity in normal and wounded skin. Fibrogenesis Tissue Repair 2008;1(1):3
   PubMedGoogle Scholar
• Thomson SE, McLennan SV, Hennessy A, et al. A novel primate model of delayed wound healing in diabetes: dysregulation of connective tissue growth factor. Diabetologia 2010;53(3):572-83
   PubMed Web of Science ®Google Scholar
• Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev 2008;19(2):133-44
   PubMed Web of Science ®Google Scholar
• Aller MA, Arias N, Fuentes-Julian S, et al. Coupling inflammation with evo-devo. Med Hypotheses 2012;78(6):721-31
   PubMed Web of Science ®Google Scholar
• Guerrot D, Dussaule JC, Kavvadas P, et al. Progression of renal fibrosis: the underestimated role of endothelial alterations. Fibrogenesis Tissue Repair 2012;5(Suppl 1):S15
   PubMedGoogle Scholar
• Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol 2011;179(3):1074-80
   PubMed Web of Science ®Google Scholar
• Moll S, Chaykovska L, Meier M, et al. Targeting the epithelial cells in fibrosis: a new concept for an old disease. Drug Discov Today 2013;18(11-12):582-91
   PubMed Web of Science ®Google Scholar
• Rucki AA, Zheng L. Pancreatic cancer stroma: understanding biology leads to new therapeutic strategies. World J Gastroenterol 2014;20(9):2237-46
   PubMed Web of Science ®Google Scholar
• Yang L, Besschetnova TY, Brooks CR, et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010;16(5):535-43; 1p following 143
   PubMed Web of Science ®Google Scholar
• Grgic I, Campanholle G, Bijol V, et al. Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int 2012;82(2):172-83
   PubMed Web of Science ®Google Scholar
• Lewis MP, Fine LG, Norman JT. Pexicrine effects of basement membrane components on paracrine signaling by renal tubular cells. Kidney Int 1996;49(1):48-58
   PubMed Web of Science ®Google Scholar
• Johnson DW, Saunders HJ, Baxter RC, et al. Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int 1998;54(3):747-57
   PubMed Web of Science ®Google Scholar
• Abbate M, Zoja C, Rottoli D, et al. Proximal tubular cells promote fibrogenesis by TGF-beta1-mediated induction of peritubular myofibroblasts. Kidney Int 2002;61(6):2066-77
   PubMed Web of Science ®Google Scholar
• Fine LG, Norman JT, Ong A. Cell-cell cross-talk in the pathogenesis of renal interstitial fibrosis. Kidney Int Suppl 1995;49:S48-50
   PubMedGoogle Scholar
• Alpers CE, Hudkins KL, Floege J, et al. Human renal cortical interstitial cells with some features of smooth muscle cells participate in tubulointerstitial and crescentic glomerular injury. J Am Soc Nephrol 1994;5(2):201-9
   PubMed Web of Science ®Google Scholar
• Chawla LS, Amdur RL, Amodeo S, et al. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 2011;79(12):1361-9
   PubMed Web of Science ®Google Scholar
• Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41(1):1-12
   PubMed Web of Science ®Google Scholar
• Xue JL, Eggers PW, Agodoa LY, et al. Longitudinal study of racial and ethnic differences in developing end-stage renal disease among aged medicare beneficiaries. J Am Soc Nephrol 2007;18(4):1299-306
   PubMed Web of Science ®Google Scholar
• Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164(6):659-63
   PubMed Web of Science ®Google Scholar
• Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33(4):278-85
   PubMed Web of Science ®Google Scholar
• Li L, Astor BC, Lewis J, et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis 2012;59(4):504-12
   PubMed Web of Science ®Google Scholar
• Hu B, Gadegbeku C, Lipkowitz MS, et al. Kidney function can improve in patients with hypertensive CKD. J Am Soc Nephrol 2012;23(4):706-13
   PubMed Web of Science ®Google Scholar
• Taal MW, Brenner BM. Renal risk scores: progress and prospects. Kidney Int 2008;73(11):1216-19
   PubMed Web of Science ®Google Scholar
• Taal MW, Brenner BM. Defining renal risk. Curr Opin Nephrol Hypertens 2007;16(6):554-6
   PubMed Web of Science ®Google Scholar
• Taal MW, Brenner BM. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int 2006;70(10):1694-705
   PubMed Web of Science ®Google Scholar
• Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009;54(2):205-26
   PubMed Web of Science ®Google Scholar
• Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011;80(1):17-28
   PubMed Web of Science ®Google Scholar
• Holtkamp FA, de Zeeuw D, de Graeff PA, et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011;32(12):1493-9
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358(23):2433-46
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367(23):2204-13
   PubMed Web of Science ®Google Scholar
• Fassett RG, Venuthurupalli SK, Gobe GC, et al. Biomarkers in chronic kidney disease: a review. Kidney Int 2011;80(8):806-21
   PubMed Web of Science ®Google Scholar
• Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014;9:157-79
   PubMed Web of Science ®Google Scholar
• Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007;176(3):277-84
   PubMed Web of Science ®Google Scholar
• Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000;161(4 Pt 1):1172-8
   PubMed Web of Science ®Google Scholar
• Young L, Adamson IY. Epithelial-fibroblast interactions in bleomycin-induced lung injury and repair. Environ Health Perspect 1993;101(1):56-61
   PubMed Web of Science ®Google Scholar
• Khalil N, O’Connor RN, Unruh HW, et al. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991;5(2):155-62
   PubMed Web of Science ®Google Scholar
• Antoniades HN, Bravo MA, Avila RE, et al. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990;86(4):1055-64
   PubMed Web of Science ®Google Scholar
• Nash JR, McLaughlin PJ, Butcher D, et al. Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis. Histopathology 1993;22(4):343-7
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29(3 Suppl):S93-7
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hagimoto N, Kawasaki M, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999;104(1):13-19
   PubMed Web of Science ®Google Scholar
• Xu MY, Porte J, Knox AJ, et al. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 2009;174(4):1264-79
   PubMed Web of Science ®Google Scholar
• Geng H, Lan R, Singha PK, et al. Lysophosphatidic acid increases proximal tubule cell secretion of profibrotic cytokines PDGF-B and CTGF through LPA2- and Galphaq-mediated Rho and alphavbeta6 integrin-dependent activation of TGF-beta. Am J Pathol 2012;181(4):1236-49
   PubMed Web of Science ®Google Scholar
• Krediet RT, Struijk DG. Peritoneal changes in patients on long-term peritoneal dialysis. Nat Rev Nephrol 2013;9(7):419-29
   PubMed Web of Science ®Google Scholar
• Kim YL. Update on mechanisms of ultrafiltration failure. Perit Dial Int 2009;29(Suppl 2):S123-7
   PubMedGoogle Scholar
• Kaneko K, Hamada C, Tomino Y. Peritoneal fibrosis intervention. Perit Dial Int 2007;27(Suppl 2):S82-6
   PubMedGoogle Scholar
• Lameire N, Van Biesen W. Epidemiology of peritoneal dialysis: a story of believers and nonbelievers. Nat Rev Nephrol 2010;6(2):75-82
   PubMed Web of Science ®Google Scholar
• Rutkowski B. Changing pattern of end-stage renal disease in central and eastern Europe. Nephrol Dial Transplant 2000;15(2):156-60
   PubMed Web of Science ®Google Scholar
• Kim SG, Kim S, Hwang YH, et al. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study). Perit Dial Int 2008;28(Suppl 3):S117-22
   PubMedGoogle Scholar
• Haag-Weber M, Kramer R, Haake R, et al. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 2010;25(7):2288-96
   PubMed Web of Science ®Google Scholar
• Schmid U, Stopper H, Heidland A, et al. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab Res Rev 2008;24(5):371-7
   PubMed Web of Science ®Google Scholar
• Kihm LP, Muller-Krebs S, Klein J, et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol 2011;22(5):914-26
   PubMed Web of Science ®Google Scholar
• Sakai N, Chun J, Duffield JS, et al. LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J 2013;27(5):1830-46
   PubMed Web of Science ®Google Scholar
• Nessim SJ, Bargman JM. The peritoneal-renal syndrome. Nat Rev Nephrol 2013;9(5):302-6
   PubMed Web of Science ®Google Scholar
• Hughes M, Herrick A. Systemic sclerosis. Br J Hosp Med (Lond) 2012;73(9):509-10; 11-6
   PubMed Web of Science ®Google Scholar
• Abraham DJ, Krieg T, Distler J, et al. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009;48(Suppl 3):iii3-7
   PubMedGoogle Scholar
• Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360(19):1989-2003
   PubMed Web of Science ®Google Scholar
• Fabre A, Marchal-Somme J, Marchand-Adam S, et al. Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice. Eur Respir J 2008;32(2):426-36
   PubMed Web of Science ®Google Scholar
• Ebrahimkhani MR, Oakley F, Murphy LB, et al. Stimulating healthy tissue regeneration by targeting the 5-HT(2)B receptor in chronic liver disease. Nat Med 2011;17(12):1668-73
   PubMed Web of Science ®Google Scholar
• Boerrigter G, Burnett JC Jr. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev 2007;25(1):30-45
   PubMedGoogle Scholar
• Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011;123(20):2263-73
   PubMed Web of Science ®Google Scholar
• Beyer C, Reich N, Schindler SC, et al. Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. Ann Rheum Dis 2012;71(6):1019-26
   PubMed Web of Science ®Google Scholar
• Wang Y, Kramer S, Loof T, et al. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Kidney Int 2005;68(1):47-61
   PubMed Web of Science ®Google Scholar
• Benz K, Orth SR, Simonaviciene A, et al. Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage. Kidney Blood Press Res 2007;30(4):224-33
   PubMed Web of Science ®Google Scholar
• System USRD. Annual Data Report 2008. USRDS - ADR; 2008
   Google Scholar
• Alport AC. Hereditary familial congenital haemorrhagic nephritis. Br Med J 1927;1(3454):504-6
   PubMedGoogle Scholar
• Gross O, Beirowski B, Koepke ML, et al. Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 2003;63(2):438-46
   PubMed Web of Science ®Google Scholar
• Flamant M, Placier S, Rodenas A, et al. Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease. J Am Soc Nephrol 2006;17(12):3374-81
   PubMed Web of Science ®Google Scholar
• Guerrot D, Kerroch M, Placier S, et al. Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am J Pathol 2011;179(1):83-91
   PubMed Web of Science ®Google Scholar
• Kerroch M, Guerrot D, Vandermeersch S, et al. Genetic inhibition of discoidin domain receptor 1 protects mice against crescentic glomerulonephritis. FASEB J 2012;26(10):4079-91
   PubMed Web of Science ®Google Scholar
• Gross O, Friede T, Hilgers R, et al. Safety and efficacy of the ACE-inhibitor ramipril in alport syndrome: the double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT alport trial in pediatric patients. ISRN Pediatr 2012;2012:436046
   Google Scholar
• Takakuta K, Fujimori A, Chikanishi T, et al. Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur J Pharmacol 2010;629(1-3):118-24
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Zhang Y, Williams SJ, et al. A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat. PLoS One 2012;7(10):e47160
   PubMed Web of Science ®Google Scholar
• Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011;22(6):1144-51
   PubMed Web of Science ®Google Scholar
• Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007;2(5):906-13
   PubMed Web of Science ®Google Scholar
• Fioretto P, Steffes MW, Sutherland DE, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998;339(2):69-75
   PubMed Web of Science ®Google Scholar
• Fioretto P, Sutherland DE, Najafian B, et al. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006;69(5):907-12
   PubMed Web of Science ®Google Scholar
• Adamczak M, Gross ML, Krtil J, et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003;14(11):2833-42
   PubMed Web of Science ®Google Scholar
• Boffa JJ, Lu Y, Placier S, et al. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003;14(5):1132-44
   PubMed Web of Science ®Google Scholar
• Ikoma M, Kawamura T, Kakinuma Y, et al. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991;40(2):195-202
   PubMed Web of Science ®Google Scholar
• Sisson TH, Mendez M, Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 2010;181(3):254-63
   PubMed Web of Science ®Google Scholar